**GENOMICS**

863 Detection of Tumor Suppressor Genes in Cancer Development by a Novel shRNA-Based Method  
Johannes von Burstin, Sandra Diersch, Günter Schneider, Maximilian Reichert, Anil K. Rustgi, and Roland M. Schmid

870 Genome-Wide Profiling of TRACK Kidneys Shows Similarity to the Human ccRCC Transcriptome  
Leiping Fu, Denise R. Minton, Tuo Zhang, David M. Nanus, and Lorraine J. Gudas

**ONCOGENES AND TUMOR SUPPRESSORS**

879 Tumor Suppressor NF2 Blocks Cellular Migration by Inhibiting Ectodomain Cleavage of CD44  
Monika Hartmann, Liseth M. Parra, Anne Ruschel, Sandra Böhme, Yong Li, Helen Morrison, Andreas Herrlich, and Peter Herrlich

891 Breast Cancer–Specific miR Signature Unique to Extracellular Vesicles Includes "microRNA-like" tRNA Fragments  
Nicole Guzman, Kitty Agarwal, Dilip Asthagiri, Lianbo Yu, Motoyasu Saji, Matthew D. Ringel, and Michael E. Paulaitis

902 The Tumor-Suppressor WWOX and HDAC3 Inhibit the Transcriptional Activity of the β-Catenin Coactivator BCL9-2 in Breast Cancer Cells  
Perla El-Hage, Ambre Petialot, Anne-Hélène Monsoro-Burq, Frédérique Maczkowiak, Keltouma Driouch, Etienne Formstecher, Jacques Camonis, Michèle Sabbah, Ivan Bitche, Rosette Lidereau, and François Lallemand

913 The Tumor Suppressor NKX3.1 Is Targeted for Degradation by DYRK1B Kinase  
Liang-Nian Song, Jose Silva, Antonius Koller, Andrew Rosenthal, Emily I. Chen, and Edward P. Gelmann

---

**CELL DEATH AND SURVIVAL**

809 HuR Suppresses Fas Expression and Correlates with Patient Outcome in Liver Cancer  
Haifeng Zhu, Zuzana Berkova, Rohit Mathur, Lalit Sehgal, Tamer Khashab, Rong-Hua Tao, Xue Ao, Lei Feng, Anita L. Sabichi, Boris Blechacz, Asif Rashid, and Felipe Samaniego

819 Variants of Osteoprotegerin Lacking TRAIL Binding for Therapeutic Bone Remodeling in Osteolytic Malignancies  
Jerome T. Higgs, John S. Jarboe, Joo Hyoung Lee, Diptiman Chanda, Carnellia M. Lee, Champion Deivanayagam, and Selvarangan Ponnazhagan

**CHROMATIN, GENE, AND RNA REGULATION**

828 The IncRNA DRAIC/PCAT29 Locus Constitutes a Tumor-Suppressive Nexus  
Kouhei Sakurai, Brian J. Reon, Jordan Anaya, and Anindya Dutta

839 lncRNA Expression Discriminates Karyotype and Predicts Survival in B-Lymphoblastic Leukemia  
Thilini R. Fernando, Norma J. Rodriguez-Malave, Ella V. Waters, Weihong Yan, David Casero, Giuseppe Basso, Martina Pigazzi, and Dinesh S. Rao

**DNA DAMAGE AND REPAIR**

852 Targeting MPS1 Enhances Radiosensitization of Human Glioblastoma by Modulating DNA Repair Proteins  
Uday Bhanu Maachani, Tamalee Kramp, Ryan Hanson, Shuping Zhao, Orieta Celiku, Uma Shankavaram, Riccardo Colombo, Natasha J. Caplen, Kevin Camphausen, and Anita Tandle

---

**Highlights of This Issue**  807
SIGNAL TRANSDUCTION

923 mTOR/MYC Axis Regulates O-GlcNAc Transferase Expression and O-GlcNAcylation in Breast Cancer
Valerie L. Sodi, Sakina Khaku, Raisa Krutilina, Luciana P. Schwab, David J. Vocadlo, Tiffany N. Seagroves, and Mauricio J. Reginato

934 MAPK7 Regulates EMT Features and Modulates the Generation of CTCs
Sarah Javaid, Jianmin Zhang, Gromoslaw A. Smolen, Min Yu, Ben S. Wittner, Anurag Singh, Kshitij S. Arora, Marissa W. Madden, Rushil Desai, Matthew J. Zubrowski, Benjamin J. Schott, David T. Ting, Shannon L. Stott, Mehmet Toner, Sridhar Ramaswamy, and Daniel A. Haber

ABOUT THE COVER
Epithelial-to-mesenchymal transition (EMT) has been implicated in tumor cell migration, invasion, and metastasis. Suppression of MAPK7 increases E-cadherin (CDH1) expression, inhibits cell migration, and reduces circulating tumor cells and the appearance of lung metastases. The cover shows immunofluorescent staining of A549 cancer cells following knockdown of MAPK7, showing increased expression of CDH1 localized to the cell membrane (CDH1, green; Vimentin, red; DAPI, blue). Please see the article by Javaid and colleagues (beginning on page 934) for more information.